New Rhein
VC Fund
Philadelphia, United States
New Rhein is a venture capital firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses that utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The companycompiles syndicates of operationally focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in the development, regulatory, reimbursement, marketing, and/or contract manufacturing. New Rhein provides an understanding of what would be attractive to strategic partners and works backward to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 64%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries New Rhein invests in
Stages New Rhein invests in
Countries New Rhein invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $12M–$197M
- Series B
- $7M–$23M
- Series C
- $21M–$45M
Investment Focus
Industry
- Medical 5 (45%)
- Biotechnology 5 (45%)
- Health Care 4 (36%)
- Therapeutics 2 (18%)
- Medical Device 2 (18%)
Stage
- Series A 3 (27%)
- Series B 3 (27%)
- Series C 2 (18%)
- Seed 1 (9%)
- Series D 1 (9%)
Country
- United States 4 (36%)
- Israel 2 (18%)
- Belgium 1 (9%)
- Switzerland 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ivan Gergel
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
| VP | Total investments: 0 | Find email | ||
Paul Navarre
Executive in Residence
|
Executive in Residence | Total investments: 0 | Find email | |
Subhanu Saxena
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Butterfly Medical
|
Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can beplaced in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe.Visit www.butterfly-medical.com for more information. | $21M / Series C / May 14, 2026 | |
Alveus Therapeutics
|
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | |
Corsair Pharma
|
Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients. | $23M / Series B / Sep 20, 2023 | |
Theranica
|
Theranica is a medical device company that has combined neuromodulation therapy with modern wireless technology to develop proprietary wearable solutions that address various medical conditions and disease states. The noninvasive and therapeutic 'smart' patches are controlled by a smartphone app to allow for personalized, portable, andaffordable care. The patch consists of a proprietary 'smart' chip that delivers electrical pulses to neuro-modulate the sensory nerves under the skin. The first application of the technology is for treatment of migraine headaches. | $45M / Series C / Aug 29, 2022 | |
|
Butterfly Medical
|
Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can beplaced in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe.Visit www.butterfly-medical.com for more information. | $7M / Series B / Oct 06, 2020 | |
American Injectables
|
American Injectables is a sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials. | Series A / Sep 24, 2020 | |
Neuraptive Therapeutics
|
Neuraptive was founded to commercialize innovative technology from the University of Texas. The company is dedicated to bringing this technology to patients. It develops novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. Its franchise therapeutics product is designedfor administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves.Founded in 2016, Neuraptive Therapeutics is headquartered in Lafayette, Colorado. | $11.5M / Series A / Dec 19, 2018 | |
|
Neuraptive Therapeutics
|
Neuraptive was founded to commercialize innovative technology from the University of Texas. The company is dedicated to bringing this technology to patients. It develops novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. Its franchise therapeutics product is designedfor administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves.Founded in 2016, Neuraptive Therapeutics is headquartered in Lafayette, Colorado. | $1M / Seed / Sep 06, 2017 | |
Softhale
|
Softhale is a medical device company focused on the development of Soft Mist Inhalation (SMI) devices for the delivery of pharmaceutical drugs to the lungs. | Series A / Nov 30, 2016 | |
Chase Pharmaceuticals
|
Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those withneuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval.Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high.Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD. | $21M / Series B / May 12, 2014 | |
| See all 11 investments → | |||
Co-Investors
aMoon Fund
1 deal together
Avego Management
1 deal together
Central Texas Angel Network
1 deal together
Cipla
1 deal together
Corundum Open Innovations
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does New Rhein invest in?
New Rhein invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is New Rhein's check size?
New Rhein typically joins rounds of $12M–$197M at Series A, $7M–$23M at Series B and $21M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Rhein participates in.
How do I contact New Rhein?
Public channels for New Rhein include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Rhein?
The team at New Rhein includes Ivan Gergel (Managing Partner), Nishant Rastogi (VP) and Paul Navarre (Executive in Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
